Added to YB: 2026-09-04
Pitch date: 2026-09-02
SGMOQ [bullish]
Sangamo Therapeutics, Inc.
-2.35%
current return
Author Info
Triple S is a professional special situations investor who shares ideas in their newsletter. Sign up for the newsletter.
Company Info
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States.
Market Cap
$67.9M
Pitch Price
$0.17
Price Target
0.57 (+233%)
Dividend
N/A
EV/EBITDA
-0.59
P/E
-0.43
EV/Sales
1.73
Sector
Biotechnology
Category
special_situation
Sangamo Bankruptcy ($SGMOQ)
SGMOQ: Sangamo’s bankrupt equity at ~$0.16 is framed as already reflecting base-case cash value from contracted asset sales, leaving the $100M Fabry approval milestones and NOL shell as upside. Expected recovery is 2.5x, or nearer 2x after omitted time and liquidation costs, with a $0.57 upside case. Estimated downside is ~30% if milestones fail, estate costs escalate or the NOLs realize little value.
Read full article (8 min)